(Nasdaq:CBMX) today announced Dr. Amit Kumar, President and CEO, will present
at the Robert W. Baird + Co. 2009 Health Care Conference, which will be held
at the Four Seasons Hotel New York, 57 East 57th Street, New York, NY. Dr. Kumar's
presentation will take place on Wednesday, September 9, 2009, at 12:15 p.m.
To attend the live webcast of Dr. Kumar's presentation, please go to http://www.wsw.com/webcast/baird9/cbmx/.
You may also listen to the webcast by going to CombiMatrix's website at http://investor.combimatrix.com/events.cfm.
The webcast will be archived for 90 days following the live presentation.
Baird is an employee-owned wealth management, capital markets, asset management
and private equity firm with client assets of more than $66 billion. Leveraging
our deep expertise and broad skills, we're dedicated to providing the best advice
and service to our individual, corporate, institutional and municipal clients.
CombiMatrix Corporation is a diversified biotechnology business that develops
proprietary technologies, including products and services in the areas of drug
development, genetic analysis, molecular diagnostics, nanotechnology and defense
and homeland security markets, as well as in other potential markets where our
products and services could be utilized. The technologies we have developed
include a platform technology to rapidly produce user-defined, in-situ synthesized,
oligonucleotide arrays for use in identifying and determining the roles of genes,
gene mutations and proteins. This technology has a wide range of potential applications
in the areas of genomics, proteomics, biosensors, drug discovery, drug development,
diagnostics, combinatorial chemistry, material sciences and nanotechnology.
Other technologies include proprietary molecular synthesis and screening methods
for the discovery of potential new drugs. Combimatrix Molecular Diagnostics,
Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California,
has developed capabilities of producing arrays that utilize bacterial artificial
chromosomes, which also enable genetic analysis. CMDX functions primarily as
a diagnostics reference laboratory. Leuchemix Inc. ("Leuchemix"),
a minority owned subsidiary, is developing a series of compounds to address
a number of oncology-related diseases. Leuchemix's first compound has entered
initial clinical trials.